ArticleIndian journal of pediatrics2026
Potential Role of Omega-3 Supplementation in Modulating Symptoms and Holter Parameters in Pediatric Inappropriate Sinus Tachycardia.
Article in Indian journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the effect of omega-3 supplementation on heart rate (HR) control and heart rate variability (HRV) in children with inappropriate sinus tachycardia (IST).
methodsThis prospective randomized controlled trial included 60 children (aged 12-16 y) diagnosed with IST. Participants were randomized into two groups: Group A received omega-3 supplementation for 3 mo, while Group B received standard follow-up without treatment. Baseline and post-treatment HR, HRV parameters [Standard deviation of NN intervals (SDNN), Root mean square of successive differences (RMSSD), pNN50], and clinical outcomes were assessed using 24-h Holter monitoring and validated scales.
resultsAfter 3 mo, the omega-3 group showed significant reductions in maximum HR (from 160.5 ± 17.9 to 142.2 ± 15.7 bpm, p = 0.000) and average HR (from 98.9 ± 4.7 to 90.7 ± 5.5 bpm, p = 0.000). HRV indices also improved significantly: SDNN (p = 0.000), RMSD (p = 0.000), and pNN50 (p = 0.000). In contrast, no significant changes were observed in the control group. Clinical improvement was significantly higher in the omega-3 group (63.3% marked improvement) compared to controls (p <0.001). Obesity (p = 0.049) and pre-hypertension (p <0.001) were associated with poor response to omega-3 therapy. No significant differences in anxiety scores were found between groups.
conclusionsOmega-3 supplementation significantly improved HR control and HRV in pediatric IST patients. Obesity and elevated blood pressure may limit treatment efficacy.
Indexed as
Identifiers
42518088What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.